Patients requiring daily systemic corticosteroids are not eligible; patients must not have received systemic corticosteroids within  days prior to enrollment; if used to modify immune adverse events related to prior therapy, >=  days must have elapsed since last dose of corticosteroid; Note: use of topical or inhaled corticosteroids will not render a patient ineligible
Has received more than  days of systemic corticosteroids for aGVHD.
Any condition that would prohibit administration of corticosteroids
Conditions that would prohibit administration of corticosteroids
Patients must not have received any immunosuppressive medication within  days prior to sub-study registration and must not be planning to receive these medications while on protocol therapy; systemic corticosteroids must be stopped at least  hours prior to sub-study registration; however, intranasal and inhaled corticosteroids are allowed at any time before and during protocol therapy
It is preferred, but not required, that corticosteroids and hydroxyurea should start only after all diagnostic samples have been obtained; however, if the patient was previously on corticosteroids and/or hydroxyurea, this is allowable provided that the patient still has measurable disease at time of the bone marrow aspirate\r\n* Corticosteroids and/or hydroxyurea, as well as any of the other therapies mentioned (with the exception of IV cyclophosphamide), may continue to be administered, at physician discretion, until  day prior to blinatumomab administration\r\n** IV cyclophosphamide must be discontinued at least  days prior to blinatumomab administration
Has received systemic immunosuppressive treatments, aside from systemic corticosteroids within three months of start of study drug
Patients receiving systemic corticosteroids (patients off steroids for at least  hours are eligible)
Has received systemic immunosuppressive treatments, aside from systemic corticosteroids, within three months of start of study drug
Are receiving increasing doses of corticosteroids
Patients must have no clinical evidence of leptomeningeal or brain metastasis causing spinal cord compression that are symptomatic or untreated or not stable for >=  months (must be documented by imaging) or requiring corticosteroids; subjects on a stable dose of corticosteroids >  month or who have been off of corticosteroids for at least  weeks can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP) medical monitor; subjects must also be off of enzyme-inducing anticonvulsants for >  weeks
Use of corticosteroids (glucocorticoids) within  days of the MILs collection
TREATMENT: Patients receiving systemic corticosteroids
Received corticosteroids within the past  week
Patients receiving systemic corticosteroids (patients off steroids for at least  hours are eligible)
Patients receiving corticosteroids are eligible for this trial
Participants who have received  or more systemic treatment for cGvHD in addition to corticosteroids  CNI for cGvHD
Patients that transition from active aGvHD to cGvHD without tapering off corticosteroids  CNI and any systemic treatment * Patients receiving up to  mg by mouth once a day of hydrocortisone (i.e., physiologic replacement dose) of corticosteroids are allowed.
No history of long-term use of corticosteroids or concurrent short term use of corticosteroids is allowed
Subjects, who have received previous systemic corticosteroids treatment or poorly absorbable corticosteroids for the treatment of aGVHD, for longer than  days ( hours).
Subject who used corticosteroids (excluding inhalers, eye-drops, and dermatologic corticosteroids) within  weeks prior to surgery;
Patient is receiving unstable or increasing doses of corticosteroids.
Systemic corticosteroids are permissible in the following circumstances:\r\n* Short course systemic corticosteroids for disease control, improvement of performance status or non-cancer indication (=<  days) must have been discontinued at least  days prior to study treatment\r\n* Ongoing administration of a stable dose of corticosteroid therapy (previously received for >=  days) is permissible provided there is evidence of measurable disease and there will be no increase in steroid dose during the clinical trial
Patients receiving systemic corticosteroids (patients off steroids for at least  hours are eligible)
No systemic corticosteroids (unless physiologic replacement dosing) within  days of enrollment
Patients who have received high doses of systemic corticosteroids for the treatment of their ATL within  weeks prior to the start of therapy
Concurrent systemic treatment or prior therapy within  weeks for SMM; NOTE: Treatment with corticosteroids for other indications is permitted
Ongoing immunosuppressive treatment at the time of the start of voruciclib therapy, including systemic or enteric corticosteroids except as follows:
During study therapy, subjects may use systemic, topical, or enteric corticosteroids, if needed
Patients receiving systemic corticosteroids greater than -weeks in duration within  months of study entry must have evidence of adequate adrenal function based upon morning plasma cortisol concentration or ACTH (cosyntropin) stimulation test
Presence of immunosuppressive conditions, including administration of any medications or treatments that may adversely affect the immune system such as allergy injections, immune globulin, interferon, immunomodulators, cytotoxic drugs, or systemic corticosteroids (oral or injectable) during  months prior to enrollment; inhaled and topical corticosteroids allowed
Current use of immunosuppressive agents or systemic corticosteroids; topical, ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal systemic absorption) are allowed; patients who have received systemic\r\ncorticosteroids =<  days prior to starting study drug will be excluded
Need for systemic treatment with corticosteroids for cGVHD
Received any previous systemic treatment for cGVHD with the exception of corticosteroids administered for cGVHD within the  hours prior to signing the informed consent form.
Corticosteroids
Concurrent systemic corticosteroids, cytokines, and immunomodulatory therapy (e.g. interferons)
Patients receiving concurrent corticosteroids at the time protocol therapy is initiated other than for physiologic maintenance treatment
No systemic corticosteroids (unless physiologic replacement dosing) within  days of enrollment
No systemic corticosteroids (unless physiologic replacement dosing) within  days of enrollment
Patients who are receiving systemic corticosteroids
Use of systemic corticosteroids
Chronically treated with systemic doses of immunosuppressive drugs such as cyclosporin, ACTH, or corticosteroids.
Any condition that requires the use of corticosteroids outside of corticosteroids defined in the protocol after day  of therapy
Patients who are on corticosteroids or immunosuppressants are not eligible; a  week wash-out period for is required before registration
Has received systemic immunosuppressive treatments, aside from systemic corticosteroids (such as methotrexate, chloroquine, azathioprine, etc) within six months of registration
% prednisolone acetate ophthalmic suspension and any other corticosteroids.
Current use of systemic corticosteroids or use of systemic corticosteroids within  weeks of enrollment (inhaled corticosteroids for asthma or chronic obstructive pulmonary disease [COPD] are permitted as are other non-systemic steroids such as topical corticosteroids)
Patients receiving active immunosuppressive agents or chronic use of systemic corticosteroids within  days of vaccine treatment\r\n* Note: special considerations for vaccination: study-related treatments may be given after short-term steroid use (=<  days) with prior approval by the protocol chair and investigational new drug (IND) sponsor
Immunosuppressive therapy including systemic corticosteroids except for maintenance dosing for adrenal insufficiency
Current use of immunosuppressive drugs or use of corticosteroids, except for inhaler, topical corticosteroids, or dexamethasone in the premedication for docetaxel.
Subject requires or is likely to require more than a two-week course of corticosteroids for intercurrent illness; subject must complete the course of corticosteroids  weeks before screening to meet eligibility
Patients being chronically treated with immunosuppressive drugs such as cyclosporin, adrenocorticotropic hormone (ACTH), or systemic corticosteroids
Conditions that would prohibit administration of corticosteroids
No systemic corticosteroids (unless physiologic replacement dosing) within  days of enrollment
Any condition that requires or is likely to require treatment with systemic corticosteroids within the core study period and short term follow-up
Subjects who require or are likely to require more than a two-week course of corticosteroids for intercurrent illness; subjects must complete therapy prior to enrollment; topical corticosteroids should be stopped at least  weeks prior to enrollment and systemic corticosteroids should be stopped at least  weeks prior to enrollment
Conditions that would prohibit intermittent administration of corticosteroids for T-DM premedication.
Patients must have no clinical evidence of leptomeningeal or brain metastasis causing spinal cord compression that are symptomatic or untreated or not stable for >=  weeks (must be documented by imaging) or requiring corticosteroids; subjects on a stable dose of corticosteroids >  month or who have been off of corticosteroids for at least  weeks can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP) medical monitor; subjects must also be off of enzyme-inducing anticonvulsants for >  weeks
Treatment with corticosteroids within  weeks prior to enrollment
Patients taking systemic corticosteroids
The use of corticosteroids to control cerebral edema or treat neurologic symptoms will not be allowed, and patients who previously required corticosteroids for symptom control must be off steroids for at least  days without recurrence of symptoms prior to starting trial therapy; corticosteroids for other indications is allowed
Current use of systemic corticosteroids
More than  weeks since prior systemic corticosteroids
Corticosteroids by aerosol are allowed
Patients who have received systemic chemotherapy (corticosteroids not included) less than  weeks prior to the start of this protocol
Any therapy =<  weeks prior to registration; NOTE: Exception: patients on ibrutinib or corticosteroids (any dose) may continue therapy up until the new regimen has started at investigator discretion; corticosteroids can be tapered to lowest possible dose after start of treatment at investigator discretion
Patients receiving unstable or increasing doses of corticosteroids
Patient received corticosteroids within  weeks prior to the first dose.
At least  weeks beyond corticosteroids.
Patients who have received corticosteroids =<  weeks prior to starting study drug; the exception is patients receiving low dose steroids for CNS disease; otherwise, systemic corticosteroids should not be administered with BKM
ORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Daily administration of systemic immunosuppressive therapy or corticosteroids (except in physiological doses for hormone deficiency) during the previous  days
Any use of systemic corticosteroids within  days of treatment initiation.
Patients requiring systemic corticosteroids (unless patients have had no corticosteroids within  weeks prior to start of study)
Subjects require or are likely to require more than a -week course of corticosteroids for intercurrent illness. Subjects must have completed the course of corticosteroids at the time of apheresis to meet eligibility.
No prior therapy is allowed except for the following:\r\n* Short courses of corticosteroid (defined as =<  days of corticosteroids within the -weeks preceding registration) are allowed\r\n** Participants who have been on corticosteroids chronically (defined as more than  days of corticosteroids within the -weeks preceding registration or more than  days of corticosteroids over the preceding  months) are not eligible; previous courses of inhaled corticosteroids of any duration are allowed\r\n* A single dose of intrathecal cytarabine (at the time of the diagnostic lumbar puncture) is allowed prior to registration; if patient has received intrathecal (IT) cytarabine prior to informed consent for protocol treatment, day  IT cytarabine should not be administered\r\n* Emergent radiation to the mediastinum or other life-threatening masses is allowed prior to registration
The subject requires or is likely to require more than a -week course of corticosteroids of >  mg
Treatment with systemic corticosteroids within  weeks prior to the start of the treatment; patients that require inhaled or low-dose corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, mineralocorticoids are allowed
Patients who are currently receiving or plan to receive corticosteroids except as described below \r\n* Systemic corticosteroids may be administered for cytoreduction up to  hours prior to the start of protocol therapy, as a premedication for InO and as treatment for allergic reactions or for physiologic replacement/stress dosing of hydrocortisone for documented adrenal insufficiency; corticosteroids are not allowed for other indications
No oral corticosteroids  days before initiating combinations TEW-/POM; inhaled corticosteroids are permitted
Has had systemic corticosteroids within  weeks of the first dose of protocol-related radiation or MK-
No prior therapy is allowed except for the following:\r\n* Corticosteroids: short courses of corticosteroid (defined as =<  days of corticosteroids within the  weeks preceding registration) are allowed prior to registration; note: if patient has received pre-treatment with corticosteroids, they should not receive steroid prophase\r\n** Participants who have been on corticosteroids chronically (defined as more than  days of corticosteroids within the  weeks preceding registration or more than  days of corticosteroids over the preceding  months) are not eligible\r\n* IT cytarabine: a single dose of intrathecal cytarabine (at the time of the diagnostic lumbar puncture) is allowed prior to registration; if patient has received IT cytarabine prior to registration, day  IT cytarabine should not be administered\r\n* Emergent radiation therapy: emergent radiation to the mediastinum or other life-threatening masses is allowed prior to registration
Participants who have received more than  days of corticosteroids in the preceding  weeks or more than  days of corticosteroids in the preceding  months are not eligible
Corticosteroids should not be used during chemotherapy administration as an antiemetic
Any condition that would prohibit administration of corticosteroids
Patient must have received no prior radiation therapy or chemotherapy other than corticosteroids; corticosteroids are allowable for all patients
Any use of systemic corticosteroids in the prior  weeks
Patients requiring treatment with corticosteroids are eligible
Patients receiving chronically dosed corticosteroids within  days prior to enrollment are not eligible for this trial
Conditions that would prohibit administration of corticosteroids
Immunosuppressive medications including systemic corticosteroids unless used for adrenal replacement, appetite stimulation, acute therapy for asthma or bronchitis exacerbation (=<  weeks), or antiemesis
Current treatment or treatment within  weeks of screening with drugs known to reduce\n             serum calcium levels, including: bisphosphonates, antiepileptic drugs, cinacalcet,\n             macrolide antibiotics (such as erythromycin, azithromycin), large doses of\n             corticosteroids (> mg/day of prednisone or equivalent), or any IV use of\n             corticosteroids. In addition, long-term use (defined as ongoing use for ? weeks) of\n             corticosteroids within  weeks of screening is prohibited
Use of systemic corticosteroids or other immunosuppressive agents within the previous  weeks of study enrollment
Patients taking systemic corticosteroids
Subjects who cannot tolerate a corticosteroid taper, that is, begin corticosteroids at . mg/kg per day, demonstrate response, but progress before a % decrease from the initial starting dose of corticosteroids is achieved.
Patients NOT receiving systemic immune suppressive therapy for treatment of active GVHD (topical skin and GI corticosteroids are allowed).
Concurrent, recent (?  weeks ago) or anticipated treatment with systemic corticosteroids at any dose, or
Requiring corticosteroids or anticonvulsants in the prior  days
Subject is currently receiving or requires treatment with immunosuppressive agents or immunosuppressive doses of systemic corticosteroids (unless used to treat drug-related adverse events).Topical, ocular, intra-articular, intranasal, inhalational corticosteroids (with minimal systemic absorption), and some uses of systemic corticosteroids are permitted as per Section ..
Concurrent, recent (?  weeks ago) or anticipated treatment with systemic corticosteroids at any dose, or
Requiring corticosteroids or anticonvulsants in the prior  days
Have had any chemotherapy or systemic corticosteroids within  weeks of study entry.
Concurrent, recent (?  weeks ago) or anticipated treatment with systemic corticosteroids at any dose, or
Daily administration of systemic immunosuppressive therapy or corticosteroids (except in physiological doses for hormone deficiency) during the previous  days.
Neurologically stable defined as receiving no, stable, or tapering doses of corticosteroids for >=  days prior to drug dosing; treatment with corticosteroids during the study is allowed, and can be adjusted by the investigator during the study; changes in steroid dose are incorporated into the Revised Assessment in Neuro-Oncology (RANO) imaging criteria
Systemic (oral or parenteral) corticosteroids within  days of study entry
Current use of systemic corticosteroids
Patients receiving corticosteroids are not eligible; patients must have been off corticosteroids for  days prior to start of chemotherapy
Subjects on systemic intravenous or oral corticosteroid therapy with the exception of physiologic doses of corticosteroids (=< the equivalent of prednisone  mg/day) or other immunosuppressives such as azathioprine or cyclosporin A are; for these subjects these excluded treatments must be discontinued at least  weeks prior to enrollment for recent short course use (=<  days) or discontinued at least  weeks prior to enrollment for long term use (>  days); in addition, the use of corticosteroids as premedication for contrast-enhanced studies is allowed prior to enrollment and on study
Concurrent or planned concurrent treatment with systemic high dose (immunosuppressive) corticosteroids or treatment with systemic corticosteroids within  weeks of baseline
Patients who have received oral or parenteral corticosteroids within  weeks of study entry or who have a clinical requirement for ongoing systemic immunosuppressive therapy not related to chemotherapy administration.
Patients on immunosuppressants, systemic corticosteroids, or any other investigational product.
Is dependent on, currently or has received within the past  weeks corticosteroids (hormone replacement therapy, topical corticosteroids and occasional inhaled corticosteroids are allowed).
Has received systemic immunosuppressive treatments, aside from systemic corticosteroids as described below (such as methotrexate, chloroquine, azathioprine, etc) within six months of start of study drug
Current or recent (=<  weeks) use of immunosuppressive medications including systemic (inhaled, oral, or intravenous [IV]) corticosteroids; Note: use of corticosteroids in doses not exceeding those used for adrenal replacement is acceptable
Systemic corticosteroids use =<  weeks, regardless of indication; note: patients who are on inhaled corticosteroids are eligible
Patients receiving concurrent corticosteroids for reason(s) other than for physiologic maintenance treatment; patients should otherwise discontinue corticosteroids prior to registration to study
Concurrent maintenance corticosteroids;
No previous use of corticosteroids for autoimmune complications that have developed since the initial diagnosis of CLL; prior use of corticosteroids for reasons other than treatment of autoimmune complications is allowed
History of long-term use of corticosteroids or concurrent short-term use of corticosteroids is not allowed; short-term corticosteroid use must be discontinued at least  weeks prior to study treatment
Brain metastases that are symptomatic or untreated or not stable for >=  months (must be documented by imaging) or requiring corticosteroids; subjects on a stable dose of corticosteroids >  month or who have been off corticosteroids for at least  weeks can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP) medical monitor; subjects must also be off enzyme-inducing anticonvulsants for >  weeks
Subjects taking chronic systemic corticosteroid therapy for any reason are not eligible. Subjects may receive steroids as prophylactic anti-emetics per the FOLFIRINOX or gemcitabine/nab-paclitaxel regimen. Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who require chronic systemic corticosteroids after beginning treatment, will be removed from study.
Treatment with corticosteroids within  weeks
Clinically stable and off corticosteroids for at least  weeks prior to study enrollment
Within  weeks of treatment initiation (day ), have received treatment with:\r\n* Local radiation therapy\r\n* UVB therapy\r\n* PUVA\r\n* Any topical chemotherapy\r\n* Photopheresis\r\n* Systemic retinoids, corticosteroids, immune response modifiers (other than imiquimod), interferon inducers, chemotherapeutic agents, biologic agents including interferon\r\n* Topical corticosteroids or retinoids
Past or current anti-cancer treatment except corticosteroids of less than  days duration in total
Currently being treated with bronchodilators or corticosteroids
Past or current anti-cancer treatment except corticosteroids during less than one week.
Long-term use of systemic corticosteroids
Patients receiving oral corticosteroids within  days of enrollment.
Subjects must be free of neurologic symptoms related to metastatic brain lesions and must not have required or received systemic corticosteroids for ? days prior to initiation of study treatment
Patients who have been treated for at least two weeks with stable doses of corticosteroids to address conditions unrelated to their malignancy will be allowed to continue this treatment during enrollment on the current trial
Require concurrent treatment with immunosuppressive agents (other than corticosteroids prescribed for a short course of therapy)
Subject requires or is likely to require more than a two week course of corticosteroids for intercurrent illness; subject must complete the course of corticosteroids  weeks before screening to meet eligibility
Supraphysiologic doses of corticosteroids within  weeks
Cytotoxic chemotherapy =<  weeks, or biologic or novel targeted therapies =<  weeks, or corticosteroids =<  weeks, prior to registration; patients may be receiving chronic corticosteroids if they are being given for disorders other than myeloma
Patients who have received systemic chemotherapy (corticosteroids not included) less than  weeks prior to the start of this protocol
Subjects with a medical condition requiring chronic systemic corticosteroids
Any other disease requiring long-term corticosteroids or immunosuppressants
Subjects must be receiving systemic corticosteroids.
Participants must be receiving systemic corticosteroids. Treatment with methylprednisolone/systemic steroids must have been initiated within  hours prior to the first dose of study treatment after enrollment
Subjects taking chronic systemic corticosteroid therapy for any reason are not eligible. Subjects may receive steroids as prophylactic anti-emetics per the mFOLFIRINOX regimen. Subjects receiving inhaled or topical corticosteroids are eligible. Subjects who require chronic systemic corticosteroids after beginning treatment, will be removed from study.
No ongoing requirement for corticosteroids
Daily requirement for corticosteroids (except for inhalation corticosteroids).
Use of topical corticosteroids at or near the intended administration site;
Patient has discontinued all corticosteroids for that indication for at least  weeks;
Patients currently receiving systemic corticosteroids
Patients on systemic corticosteroids (except for patients on stable doses of hormone replacement therapy such as hydrocortisone), or other immunosuppressants (e.g., infliximab, mycophenolate mofetil) are excluded
No systemic or inhaled corticosteroids within  days prior to initiation of protocol therapy; NOTE: use of topical corticosteroids and/or eye drops containing glucocorticosteroids is acceptable
For patients on corticosteroids, they must have been on a fixed dose for  week prior to entry if clinically recommended
Patients on corticosteroids for any reason
Patients who have received systemic corticosteroids =<  weeks prior to starting study drug; systemic corticosteroids should not be administered with BKM (usage of steroids as premedications and anti-emetics for paclitaxel and carboplatin, per MSKCC guidelines, is allowed; steroids given as part of pre-medications for imaging studies are not exclusionary)
Patients taking systemic corticosteroids
Corticosteroids discontinued ? days of initiating therapy
patients receiving hydroxyurea or corticosteroids that has not been discontinued at least  week after initiation of nilotinib
Prior corticosteroids allowed
Patients must not require use of systemic corticosteroid within  days prior to registration or during protocol treatment; patients with preexisting severe autoimmune disease requiring systemic corticosteroids or ongoing immunosuppression are not eligible
Patients must not be receiving any of the following concomitant medications:\r\n* Pharmacologic doses of systemic corticosteroids unless for CNS metastatic or primary disease; for patients with CNS metastatic or primary tumors receiving corticosteroids, they should be on a stable or decreasing dose over the  days prior to registration; for all patients, receipt of systemic physiologic replacement steroids, topical, and/or inhaled corticosteroids is acceptable\r\n* Non-steroidal anti-inflammatory drugs, oral anticoagulants, and therapeutic heparins
Treatment with high dose systemic corticosteroids or continuous use of other immunosuppressants within the past  days
Current use of corticosteroids defined as oral, intravenous (IV), or injections of corticosteroids in the past  weeks\r\n* If the patient is only prescribed a short-term, time-limited dose of oral, intravenous (IV), or injections of corticosteroids, then they may be rescreened for eligibility once they are >=  weeks post-completion of their course of corticosteroids
Use of oral corticosteroids or topical corticosteroids in the irradiation area
Short course systemic corticosteroids is permissible for disease control, improvement of performance status or non-cancer indication if =<  days and must be discontinued prior to study treatment
Patients must not have received oral corticosteroids, intramuscular corticosteroids, or intra-articular steroids for joint symptoms within  days prior to registration
Treatment with high dose systemic corticosteroids or continuous use of other immunosuppressants within the past  months
Autoimmune disorders, transplant recipients, other immunosuppression including any concurrent condition requiring the use of immunosuppressive/ immunomodulating agents; Exception: eye drop-containing and infrequent inhaled corticosteroids are permissible; topical corticosteroids are permissible at locations other than the administration site (upper arm); Note: All systemic corticosteroids must be discontinued at least  weeks prior to randomization; inhaled corticosteroids must be discontinued >=  hours prior to randomization and courses of more than  weeks are not permissible within  weeks of randomization
Patients on systemic corticosteroids (oral or intravenous)
Skin conditions that require consistent use of topical corticosteroids or other local or systemic therapy that may interfere with interpretation or description of skin-related adverse events linked to vaccination
Any use of oral corticosteroids =<  weeks prior to registration/randomization
Use of any systemic antineoplastic or immunomodulatory treatment, systemic corticosteroids for greater than  days, investigational vaccines, interleukins, interferons, growth factors, or intravenous immunoglobulin (IVIG) within  days prior to study entry
Immunosuppressive therapy including systemic corticosteroids except for maintenance dosing for adrenal insufficiency
Treatment within  months with immunomodulatory therapy (e.g., interferons, immunoglobulin therapy, interleukin  receptor antagonist or systemic corticosteroids); short-term systemic corticosteroids or topical or intra-articular steroids are acceptable, at the discretion of the Investigator
Current or prior systemic use of corticosteroids in the past month
Corticosteroids: no restrictions
currently or previously required systemic immunosuppressive or immunomodulatory therapy (including corticosteroids administered by systemic route) and/or
